Smati S, Sotin T, Deniel P, Ducheix S, et al. Empagliflozin mitigates metabolic dysfunction-associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes. Diabetes Obes Metab 2024 May 3. doi: 10.1111/dom.15634.
PMID: 38699785